Preclinical News and Research

RSS

BioLineRx reports positive results from pre-clinical trials with RHB-104 for treatment of thrombocytopenia

BioLineRx, a biopharmaceutical development company, announced today that BL-8040 has been shown in pre-clinical trials to be effective for the treatment of thrombocytopenia, or reduced platelet production.

5 Aug 2013

Compugen, Bayer sign collaboration and license agreement for antibody-based cancer immunotherapies

Compugen Ltd. announced today the signing of a collaboration and license agreement for the research, development, and commercialization of antibody-based therapeutics for cancer immunotherapy against two novel Compugen discovered immune checkpoint regulators.

5 Aug 2013

ImmunoGen reports net loss of $21.9 million in Q4 2013

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload antibody-drug conjugate technology, today reported financial results for the three-month period and fiscal year ended June 30, 2013. ImmunoGen also provided guidance for its 2014 fiscal year and an update on the Company.

2 Aug 2013

Scientists prevent cell sleep to reduce chance of tumor recurrence

An international research team led by University of Pittsburgh Cancer Institute (UPCI) scientists discovered that by preventing cancer cells from entering a state of cellular sleep, cancer drugs are more effective, and there is a lower chance of cancer recurrence.

2 Aug 2013

Trace substance in sugar improves muscle regeneration in mouse model with muscular dystrophy

A trace substance in caramelized sugar, when purified and given in appropriate doses, improves muscle regeneration in a mouse model of Duchenne muscular dystrophy. The findings are published today, Aug. 1, in the journal Skeletal Muscle.

2 Aug 2013

Researchers show that JQ1 drug can block molecular pathway responsible for heart failure

Researchers from Case Western Reserve University School of Medicine and the Dana-Farber Cancer Institute have made a fundamental discovery relevant to the understanding and treatment of heart failure - a leading cause of death worldwide. The team discovered a new molecular pathway responsible for causing heart failure and showed that a first-in-class prototype drug, JQ1, blocks this pathway to protect the heart from damage.

2 Aug 2013

Viropharma announces financial results for second quarter of 2013

VIROPHARMA INCORPORATED (Nasdaq: VPHM) today announced financial results for the second quarter of 2013. Net sales were $104 million for the second quarter ended June 30, 2013 as compared to $95 million in the comparative period of 2012.

1 Aug 2013

Miniscule signaling molecule plays critical role in certain acute and chronic diseases

Scientists seeking to harness the healing power of a miniscule signaling molecule that plays a critical role in certain acute and chronic diseases have been awarded a Program Project Grant (PPG) of nearly $10 million by the National Heart, Lung and Blood Institute of the National Institutes of Health.

1 Aug 2013

Severe arthritis pain treatments: an interview with Professor Walsh, University of Nottingham and Professor Wood, UCL

Pain is defined by the sufferer’s experience. Pain may be severe because it is intense, frequent or sustained, and because it is distressing. The severity of pain is not simply due to what is going on in the joint, but is also affected by how the body processes the pain signals, and the context in which it is experienced.

31 Jul 2013

Research finds potential long-term effects of marijuana use in adolescence

Regular marijuana use in adolescence, but not adulthood, may permanently impair brain function and cognition, and may increase the risk of developing serious psychiatric disorders such as schizophrenia, according to a recent study from the University of Maryland School of Medicine.

25 Jul 2013

Mda-9/syntenin helps regulate bladder cancer growth and metastasis

Scientists from Virginia Commonwealth University Massey Cancer Center have provided evidence from preclinical experiments that a gene known as melanoma differentiation associated gene-9/syntenin (mda-9/syntenin) could be used as a therapeutic target to kill bladder cancer cells, help prevent metastasis and even be used to non-invasively diagnose the disease and monitor its progression.

25 Jul 2013

Child cancer survival: an interview with Prof Kathy Pritchard-Jones, University College London

Back in the early 1960s, just before chemotherapy really started to be used, only about 30% of children survived cancer. That was mainly because they had cancers that were amenable to surgery.

24 Jul 2013

Inovio plans to advance synthetic hTERT cancer vaccine into clinical trials in 2014

Inovio Pharmaceuticals, Inc. announced today that in a preclinical study with two animal models, Inovio's hTERT (human telomerase reverse transcriptase) DNA cancer vaccine administered with Inovio's CELLECTRA adaptive electroporation delivery technology generated robust and broad immune responses, broke the immune system's tolerance to its self-antigens, induced T-cells with a tumor-killing function, and increased the rate of survival.

24 Jul 2013

New procedures to improve quality and usefulness of preclinical efficacy studies

Only 11% of drugs that enter clinical trials in humans are ultimately found safe and effective enough to receive regulatory approval.

24 Jul 2013

Research team receives NCI grant to develop precision therapies that kill cancer cells

A research team headed by Fred Hutchinson Cancer Research Center scientists Christopher Kemp, Ph.D., and Carla Grandori, M.D., Ph.D., has received a $4 million grant from the National Cancer Institute to develop precision therapies that selectively kill cancer cells while sparing normal, healthy tissue.

24 Jul 2013

Serum Institute of India secures license to patents, technologies related to tuberculosis vaccine

Hopes are high for a new and improved tuberculosis vaccine: Serum Institute of India is planning on taking a promising vaccine - originally developed in Germany - and introducing it into the clinical setting.

23 Jul 2013

BioCryst completes BCX4161 Phase 1 clinical trial for treatment of hereditary angioedema

BioCryst Pharmaceuticals, Inc. announced that the randomized, placebo-controlled, Phase 1 clinical trial of orally-administered BCX4161 in healthy volunteers successfully met all of its objectives.

22 Jul 2013

Kala Pharmaceuticals to present preclinical data on mucosal-penetrating particle technology

Kala Pharmaceuticals, Inc., a leading developer of innovative products that rapidly and effectively penetrate the mucosal barrier to treat ocular diseases, announced today that Kala researchers will present preclinical data at the upcoming Controlled Release Society (CRS) 2013 Annual Meeting taking place July 21-24, 2013, in Honolulu, HI.

20 Jul 2013

Nanotechnology drug kills brain-tumor cells and retards growth of tumor blood vessels

An experimental drug in early development for aggressive brain tumors can cross the blood-brain tumor barrier and kill tumor cells and block the growth of tumor blood vessels, according to a study led by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James).

19 Jul 2013

WuXi buys Provantis Portal Remote Study Monitoring solution from Instem

Instem, a leading provider of IT solutions to the global early development healthcare market, announced today that WuXi AppTec, a leading supplier of R&D services to the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, has purchased the Provantis Portal Remote Study Monitoring solution.

19 Jul 2013

Preclinical News and Research

BioLineRx reports positive results from pre-clinical trials with RHB-104 for treatment of thrombocytopenia

Compugen, Bayer sign collaboration and license agreement for antibody-based cancer immunotherapies

ImmunoGen reports net loss of $21.9 million in Q4 2013

Scientists prevent cell sleep to reduce chance of tumor recurrence

Trace substance in sugar improves muscle regeneration in mouse model with muscular dystrophy

Researchers show that JQ1 drug can block molecular pathway responsible for heart failure

Viropharma announces financial results for second quarter of 2013

Miniscule signaling molecule plays critical role in certain acute and chronic diseases

Severe arthritis pain treatments: an interview with Professor Walsh, University of Nottingham and Professor Wood, UCL

Research finds potential long-term effects of marijuana use in adolescence

Mda-9/syntenin helps regulate bladder cancer growth and metastasis

Child cancer survival: an interview with Prof Kathy Pritchard-Jones, University College London

Inovio plans to advance synthetic hTERT cancer vaccine into clinical trials in 2014

New procedures to improve quality and usefulness of preclinical efficacy studies

Research team receives NCI grant to develop precision therapies that kill cancer cells

Serum Institute of India secures license to patents, technologies related to tuberculosis vaccine

BioCryst completes BCX4161 Phase 1 clinical trial for treatment of hereditary angioedema

Kala Pharmaceuticals to present preclinical data on mucosal-penetrating particle technology

Nanotechnology drug kills brain-tumor cells and retards growth of tumor blood vessels

WuXi buys Provantis Portal Remote Study Monitoring solution from Instem

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics